The Promise of Pharmacoepidemiology in Helping Clinicians Assess Drug RiskAVORN, Jerry.Circulation (New York, N.Y.). 2013, Vol 128, Num 7, pp 745-748, issn 0009-7322, 4 p.Article

Paying for drug approvals - : Who's using whom?AVORN, Jerry.The New England journal of medicine. 2007, Vol 356, Num 17, pp 1697-1700, issn 0028-4793, 4 p.Article

Highlights and a hidden hazard : The FDA's new labeling regulationsAVORN, Jerry; SHRANK, William.The New England journal of medicine. 2006, Vol 354, Num 23, pp 2409-2411, issn 0028-4793, 3 p.Article

Internet marketing of herbal productsMORRIS, Charles A; AVORN, Jerry.JAMA, the journal of the American Medical Association. 2003, Vol 290, Num 11, pp 1505-1509, issn 0098-7484, 5 p.Article

A review of uses of health care utilization databases for epidemiologic research on therapeuticsSCHNEEWEISS, Sebastian; AVORN, Jerry.Journal of clinical epidemiology. 2005, Vol 58, Num 4, pp 323-337, issn 0895-4356, 15 p.Article

Using Computer-Based Decision Support to Close the Know-Do Gap in Lipid-Lowering TherapyAVORN, Jerry; CHOUDHRY, Niteesh K.Circulation (New York, N.Y.). 2008, Vol 117, Num 3, pp 336-337, issn 0009-7322, 2 p.Article

Over-the-counter statinsCHOUDHRY, Niteesh K; AVORN, Jerry.Annals of internal medicine. 2005, Vol 142, Num 11, pp 910-913, issn 0003-4819, 4 p.Article

University-based science and biotechnology products: Defining the boundaries of intellectual propertyKESSELHEIM, Aaron S; AVORN, Jerry.JAMA, the journal of the American Medical Association. 2005, Vol 293, Num 7, pp 850-854, issn 0098-7484, 5 p.Article

Economic implications of evidence-based prescribing for hypertension: Can better care cost less?FISCHER, Michael A; AVORN, Jerry.JAMA, the journal of the American Medical Association. 2004, Vol 291, Num 15, pp 1850-1856, issn 0098-7484, 7 p.Article

Origins of Medical Innovation: The Case of Coronary Artery StentsSHUAI XU; AVORN, Jerry; KESSELHEIM, Aaron S et al.Circulation. Cardiovascular quality and outcomes (Print). 2012, Vol 5, Num 6, pp 743-749, issn 1941-7713, 7 p.Article

Drug-Review Deadlines and Safety ProblemsCARPENTER, Daniel; ZUCKER, Evanjames; AVORN, Jerry et al.The New England journal of medicine. 2008, Vol 358, Num 13, pp 1354-1361, issn 0028-4793, 8 p.Article

Comparing the costs, risks, and benefits of competing strategies for the primary prevention of venous thromboembolismAVORN, Jerry; WINKELMAYER, Wolfgang C.Circulation (New York, N.Y.). 2004, Vol 110, Num 24, pp IV.25-IV.32, issn 0009-7322, SUPArticle

New FDA Breakthrough-Drug Category — Implications for PatientsDARROW, Jonathan J; AVORN, Jerry; KESSELHEIM, Aaron S et al.The New England journal of medicine. 2014, Vol 370, Num 13, pp 1252-1258, issn 0028-4793, 7 p.Article

Characteristics of Clinical Trials to Support Approval of Orphan vs Nonorphan Drugs for CancerKESSELHEIM, Aaron S; MYERS, Jessica A; AVORN, Jerry et al.JAMA, the journal of the American Medical Association. 2011, Vol 305, Num 22, pp 2320-2326, issn 0098-7484, 7 p.Article

Pharmacological Management of Osteoporosis in Nursing Home Populations : A Systematic ReviewPARIKH, Seema; AVORN, Jerry; SOLOMON, Daniel H et al.Journal of the American Geriatrics Society. 2009, Vol 57, Num 2, pp 327-334, issn 0002-8614, 8 p.Article

Medication-attributed adverse effects in placebo groups : Implications for assessment of adverse effectsRIEF, Winfried; AVORN, Jerry; BARSKY, Arthur J et al.Archives of internal medicine (1960). 2006, Vol 166, Num 2, pp 155-160, issn 0003-9926, 6 p.Article

Chronic kidney disease as a risk factor for bleeding complications after coronary artery bypass surgeryWINKELMAYER, Wolfgang C; LEVIN, Raisa; AVORN, Jerry et al.American journal of kidney diseases. 2003, Vol 41, Num 1, pp 84-89, issn 0272-6386, 6 p.Article

Balancing the cost and value of medications. The dilemma facing cliniciansAVORN, Jerry.PharmacoEconomics (Auckland). 2002, Vol 20, pp 67-72, issn 1170-7690, 6 p., SUP3Conference Paper

The economic consequences of non-evidence-based clopidogrel useCHOUDHRY, Niteesh K; LEVIN, Raisa; AVORN, Jerry et al.The American heart journal. 2008, Vol 155, Num 5, pp 904-909, issn 0002-8703, 6 p.Article

The nephrologist's role in the management of calcium-phosphorus metabolism in patients with chronic kidney diseaseWINKELMAYER, Wolfgang C; LEVIN, Raisa; AVORN, Jerry et al.Kidney international. 2003, Vol 63, Num 5, pp 1836-1842, issn 0085-2538, 7 p.Article

Effect of content and format of prescription drug labels on readability, understanding, and medication use : A systematic reviewSHRANK, William; AVORN, Jerry; ROLON, Cony et al.The Annals of pharmacotherapy. 2007, Vol 41, Num 5, pp 783-801, issn 1060-0280, 19 p.Article

Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel With Proton Pump Inhibitors After Percutaneous Coronary Intervention or Acute Coronary SyndromeRASSEN, Jeremy A; CHOUDHRY, Niteesh K; AVORN, Jerry et al.Circulation (New York, N.Y.). 2009, Vol 120, Num 23, pp 2322-2329, issn 0009-7322, 8 p.Article

Poor short-term survival and low use of cardiovascular medications in elderly dialysis patients after acute myocardial infarctionWINKELMAYER, Wolfgang C; CHARYTAN, David M; LEVIN, Raisa et al.American journal of kidney diseases. 2006, Vol 47, Num 2, pp 301-308, issn 0272-6386, 8 p.Article

Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibrationSTÜRMER, Til; SCHNEEWEISS, Sebastian; AVORN, Jerry et al.American journal of epidemiology. 2005, Vol 162, Num 3, pp 279-289, issn 0002-9262, 11 p.Article

Therapeutic delay and reduced functional status six months after thromabolysls for acute myocardial infarctionAVORN, Jerry; KNIGHT, Eric; GANZ, David A et al.The American journal of cardiology. 2004, Vol 94, Num 4, pp 415-420, issn 0002-9149, 6 p.Article